

1 **Vaccine serologic responses among transplant patients associate with COVID-19**  
2 **infection and T peripheral helper cells**

3  
4 Jacob E. Lemieux<sup>1,2,3#</sup>, Amy Li<sup>4</sup>, Matteo Gentili<sup>3</sup>, Cory A. Perugino<sup>2,5,6</sup>, Zoe F. Weiss<sup>1</sup>, Kathryn  
5 Bowman<sup>1</sup>, Pierre Ankomah<sup>1</sup>, Hang Liu<sup>5</sup>, Gregory D. Lewis<sup>2,7</sup>, Natasha Bitar<sup>1</sup>, Taryn Lipiner<sup>1</sup>,  
6 Nir Hacohen<sup>1,2,3</sup>, Shiv S. Pillai<sup>2,3,5</sup>, Marcia B. Goldberg<sup>1,2,3,8#</sup>

7 <sup>1</sup> Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital,  
8 Boston, MA 02114, USA; <sup>2</sup> Department of Medicine, Harvard Medical School, Boston, MA  
9 02115, USA; <sup>3</sup> The Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard,  
10 Cambridge, MA 02138, USA; <sup>4</sup> Department of Pediatrics, Boston Children's Hospital, Boston,  
11 MA 02115, USA; <sup>5</sup> Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; <sup>6</sup>  
12 Division of Rheumatology Allergy and Immunology, Massachusetts General Hospital, Boston,  
13 MA 02114; <sup>7</sup> Heart Transplant Program, Department of Medicine, Massachusetts General  
14 Hospital, Boston, MA 02114, USA; <sup>8</sup> Department of Microbiology, Harvard Medical School,  
15 Boston, MA 02115, USA

16 # Corresponding authors: Division of Infectious Diseases, Massachusetts General Hospital, 55  
17 Fruit St., Boston, MA, 02114, USA, [jlemieux@partners.org](mailto:jlemieux@partners.org) and  
18 [marcia.goldberg@mg.harvard.edu](mailto:marcia.goldberg@mg.harvard.edu)

19 Conflict of Interest statement: The authors have declared that no conflict of interest exists.

20 **Abstract**

21 **Background:** Therapeutically immunosuppressed transplant recipients exhibit attenuated  
22 responses to COVID-19 vaccines. To better understand the immune alterations that determined

23 poor vaccine response, we correlated quantities of circulating T and B cell subsets at baseline  
24 with longitudinal serologic responses to SARS-CoV-2 mRNA vaccination in heart and lung  
25 transplant recipients.

26 **Methods:** Samples at baseline and at approximately 8 and 30 days after each vaccine dose for 22  
27 heart and lung transplant recipients with no history of COVID-19, four heart and lung transplant  
28 recipients with prior COVID-19 infection, and 12 healthy controls undergoing vaccination were  
29 analyzed. Anti-spike protein receptor binding domain (RBD) IgG and pseudovirus neutralization  
30 activity were measured. Proportions of B and T cell subsets at baseline were comprehensively  
31 quantitated.

32 **Results:** At 8-30 days post vaccination, healthy controls displayed robust anti-RBD IgG  
33 responses, whereas heart and lung transplant recipients showed minimally increased responses.  
34 A parallel absence of activity was observed in pseudovirus neutralization. In contrast, three of  
35 four (75%) transplant recipients with prior COVID-19 infection displayed robust responses at  
36 levels comparable to controls. Baseline levels of activated PD-1<sup>+</sup> HLA-DR<sup>+</sup> CXCR5<sup>-</sup> CD4<sup>+</sup> T  
37 cells (also known as T peripheral helper [T<sub>PH</sub>] cells) and CD4<sup>+</sup> T cells strongly predicted the  
38 ability to mount a response.

39 **Conclusions:** Immunosuppressed patients have defective vaccine responses but can be induced  
40 to generate neutralizing antibodies after SARS-CoV-2 infection. Strong correlations of vaccine  
41 responsiveness with baseline T<sub>PH</sub> and CD4<sup>+</sup> T cell numbers highlights a role for T helper activity  
42 in B cell differentiation into antibody secreting cells during vaccine response.

## 43 **Introduction**

44 For immunocompetent individuals, SARS-CoV-2 vaccination is a highly effective preventative  
45 approach for protection from COVID-19 (1–3). However, because Phase 3 trials excluded  
46 immunosuppressed individuals, the approach to and determinants of induction of protective  
47 immunity against SARS-CoV-2 among transplant recipients and other severely  
48 immunosuppressed individuals is less clear.

49 Heart and lung transplant recipients require a higher degree of immunosuppression to prevent  
50 graft rejection than other solid organ transplant recipients. Their regimens typically include a  
51 calcineurin inhibitor (tacrolimus more often than cyclosporine), a DNA synthesis inhibitor  
52 (mycophenolate more often than azathioprine) and/or a mammalian target of rapamycin (mTOR)  
53 inhibitor (sirolimus), and low-dose glucocorticoids. Whereas both DNA synthesis inhibitors and  
54 calcineurin inhibitors block T cell expansion, tacrolimus may particularly impact follicular  
55 helper T cells (4), which are critical for the affinity maturation and isotype switching of an  
56 effective antibody response. Loss of mTOR activity not only blunts T and B cell proliferation,  
57 but also impairs the development of CD8<sup>+</sup> T cell memory (5), skews helper T cell differentiation  
58 toward regulatory T cells (6, 7), and disrupts B cell progression through germinal center  
59 reactions, including class switching and somatic hypermutation (8–10). Furthermore,  
60 glucocorticoids interfere with activities of virtually all immune cells.

61 Previous to COVID-19, several reports demonstrated attenuated or delayed serologic responses  
62 to various vaccines among severely immunosuppressed hosts (11–15). Vaccine efficacy in this  
63 patient population may depend in part on the nature of the vaccine and is sometimes improved by  
64 booster vaccination (16). Published data on antibody responses to SARS-CoV-2 mRNA

65 vaccination in transplant recipients indicate major impairments in vaccine-induced humoral and  
66 cellular immunity (16–25). Whether transplant recipients are uniquely vulnerable to more  
67 transmissible viral strains with spike protein variants, which are rising in prevalence globally,  
68 remains unclear. Hence, there is an urgency to determine why transplant recipients do not  
69 respond to standard SARS-CoV-2 mRNA vaccinations and to identify solutions to protect this  
70 vulnerable patient population.

71 Here, we quantitatively assessed the antibody response to SARS-CoV-2 vaccination among heart  
72 and lung transplant recipients, including neutralization activity to emerging variants of concern,  
73 extending recent findings from other groups (17, 22–25). Further, to identify cellular correlates  
74 of adaptive immune determinants of vaccine responsiveness, we quantified subsets of CD4<sup>+</sup> T  
75 helper cells, CD8<sup>+</sup> T cells, and B cells at baseline and correlated these with levels of serum IgG.

76 **Results**

77 **Serum IgG responses among vaccinated heart and lung transplant recipients were**  
78 **markedly diminished compared to those of healthy controls.** Among vaccinated heart and  
79 lung transplant recipients with no evidence of prior or intercurrent (between vaccine doses)  
80 COVID-19 infection (N=16 heart and N=6 lung transplant recipients), levels of IgG recognizing  
81 the SARS-CoV-2 RBD were markedly lower than those of healthy controls (Fig. 1). At 8 and 30  
82 days after the second vaccine dose, IgG anti-RBD levels were 22-fold lower ( $p = 2.9 \times 10^{-7}$ ;  
83 Wilcoxon rank-sum test) and 20-fold lower ( $p = 6.7 \times 10^{-4}$ ; Wilcoxon rank-sum test),  
84 respectively, among transplant recipients compared to those of healthy controls.

85 **Neutralization activity of plasma from vaccinated heart and lung transplant recipients**  
86 **were markedly diminished compared to that of healthy controls.** Neutralization activity to  
87 SARS-CoV-2 pseudovirus among vaccinated heart and lung transplant recipients largely  
88 paralleled IgG levels. At 8 days after the second vaccine dose, mean neutralizing antibody  
89 activity of transplant recipients was 12.2-fold less than that of healthy controls ( $p = 2.9 \times 10^{-7}$ ,  
90 Wilcoxon rank-sum test, Fig. 2A), and at 30 days after the second vaccine dose, neutralizing  
91 antibody activity of transplant recipients was 12.0-fold less than that of healthy controls  
92 (Wilcoxon rank-sum test,  $p = 0.001$ , Fig. 2B).

93 Similar to previously published results (26–31), among healthy controls, neutralizing activity to  
94 variant pseudoviruses containing the E484K/N501Y/D614G mutations present in the beta  
95 (B.1.351) and gamma (P.1) variants (originally identified in South Africa and Brazil,  
96 respectively) were reduced (Fig. S1C). Among control patients at later time points (1d pre dose 2  
97 through 68d post dose 2), neutralization against E484K/N501Y/D614G pseudovirus was 22%

98 lower than against D614G pseudovirus ( $p = 6.6 \times 10^{-6}$ , paired Wilcoxon test) and 24% lower than  
99 against N501Y/D614G pseudovirus ( $p = 3.8 \times 10^{-5}$ , paired Wilcoxon test) (Fig. S1C),  
100 representative of the alpha (B.1.1.7) variant originally identified in the United Kingdom; the  
101 difference in neutralization between D614G and N501Y/D614G pseudoviruses was not  
102 significant. Among both transplant recipients and healthy controls, neutralizing antibody titers  
103 correlated strongly with levels of anti-RBD IgG, although this correlation decreased with  
104 additional variant mutations in the RBD (Fig. S2).

105 **Time course of response.** The differences in responses between the transplant recipients and the  
106 healthy controls were evident as early as 20 days after the first vaccine dose (1 day prior to the  
107 second vaccine dose), when all but two healthy controls yet none of the transplant recipients  
108 displayed increases in IgG above background (Figs. 3, S3, and S4). Following the second dose of  
109 vaccine, IgG levels and neutralization activity progressively increased in two COVID-19-  
110 uninfected transplant recipients and all of the controls (Figs. 3 and S4). Increases in  
111 neutralization activity correlated highly with the increases in IgG levels (for D614G pseudovirus  
112 and IgG levels,  $R=0.88$ , Fig. S2A). The increases in these two transplant recipients were delayed  
113 compared to the controls; whether they will continue to increase at later times will be determined  
114 with additional follow-up. Consistent with prior publications in which lower immunosuppression  
115 is associated with improved serologic responses (17, 22–24), these two transplant recipients were  
116 on levels of immunosuppression at the lower end of our cohort; one was not on a DNA synthesis  
117 inhibitor, and both were on only 5 mg daily of prednisone.

118 **Prior or intercurrent infection with COVID-19 is associated with strong serological**  
119 **responses and neutralizing activity.** Three transplant recipients had COVID-19 prior to  
120 vaccination, and one had COVID-19 between the first and second vaccine dose. Three of these

121 four transplant recipients displayed IgG levels and neutralization activity were comparable to  
122 those of healthy controls (Fig. 3B, 3D). For the three of these individuals who displayed elevated  
123 IgG levels and neutralization activity, vaccination *per se* was associated with a boost in IgG  
124 levels, and for one, a boost in neutralization activity; for the other two who responded, it was not  
125 possible to determine whether neutralization activity was boosted, as it was >95% at baseline  
126 (Fig. 3D). The proportion of subjects who responded to vaccination was significantly different  
127 among transplant patients with prior COVID-19 ( $p = 0.018$ , Fisher's exact test). Proximity to  
128 transplantation and the higher doses of immunosuppressive medications generally administered  
129 around transplantation may have contributed to the absence of response in the COVID-19-  
130 infected non-responder, as this individual developed infection <1 year after transplantation,  
131 whereas the other three COVID-19-infected transplant recipients developed infection 2-5 years  
132 (N=2) and >15 years (N=1) after transplantation. No differences in immunosuppressive regimens  
133 at the time of vaccination or the severity of COVID-19 infection between the one COVID-19-  
134 infected non-responder and the three COVID-19-infected responders were identified. Nor were  
135 any differences in immunosuppressive regimens identified between the COVID-19-infected and  
136 uninfected transplant recipients.

137 **Peripheral blood immune cell populations at early time points and cellular predictors of**  
138 **antibody response.** To identify differences that may underlie the differential response to  
139 vaccination, we performed high-dimensional flow cytometry on baseline samples and quantified  
140 peripheral blood immune cell subsets at early time points. We found significant differences in  
141 peripheral blood immune cells including CD3<sup>+</sup> lymphocytes ( $p = 0.04$ , wilcoxon test), CD4<sup>+</sup> T  
142 lymphocytes ( $p = 0.002$ ), T peripheral helper (T<sub>PH</sub>) cells, Tregs ( $p = 0.02$ ) and DR<sup>+</sup> T cells ( $p =$   
143  $0.0059$ ). The relative proportion of T<sub>PH</sub>/CD4<sup>+</sup> ( $p = 0.0093$ ), DR<sup>+</sup>/Tregs ( $p = 0.00031$ ), and

144 DR+/CD4+ ( $p = 0.04$ ) were also decreased among transplant patients as compared to controls  
145 (Fig. 4A and S5A). In contrast, we did not observe significant differences in CD8+ T cells and  
146 CD19+ B cell populations. To identify potential cellular predictors of the antibody response to  
147 vaccination, we computed correlation statistics between baseline flow cytometry and antibody  
148 response at 8 days post second dose (Fig. S5B). Most strongly correlated with antibody response  
149 was the absolute number of T peripheral helper ( $T_{PH}$ ) cells (Pearson correlation coefficient,  $r =$   
150  $0.72$ ,  $p = 0.0036$ ), and this relationship held for the proportion of  $T_{PH}$  cells among total CD4+  
151 cells ( $r = 0.62$ ,  $p = 0.02$ ).  $T_{PH}$  cells are PD-1+ CXCR5- HLA-DR+ CD4+ T cells and represent a  
152 subset of CD4+ T cells that have been shown to drive B cell differentiation into antibody  
153 secreting cells (32). A substantial yet weaker relationship was present between day 8 IgG levels  
154 and HLA DR+ CD4+ T cells (Fig. 4B).

155 We observed no significant correlations between serologic responses and the baseline  
156 proportions of total effector-memory CD4+ T cells, regulatory T cells, HLA-DR+ (activated)  
157 regulatory T cells, naïve CD4+ T cells, or circulating T follicular helper T cells among total  
158 CD4+ T cells, effector-memory CD8+ T cells, CD8+ cytotoxic T cells, or CD8+ naïve T cells  
159 among total CD8+ T cells, naïve, unswitched memory, switched memory, or double-negative  
160 (IgD-CD27-) B cells among total CD19+ B cells.



161 **Discussion**

162 In this study, we provide the first in-depth longitudinal comparison of immune responses to  
163 SARS-CoV-2 vaccination in heart and lung transplant recipients to responses to vaccination of  
164 healthy controls and of heart and lung transplant recipients with prior COVID-19 infection. In  
165 addition, we provide the first correlation of these responses to quantitative analyses of baseline T  
166 and B cell subsets. Consistent with findings of other investigators (16–25), we show that  
167 COVID-19-naïve heart and lung transplant recipients have a profound reduction in neutralizing  
168 antibodies against SARS-CoV-2 spike protein and receptor binding domain (RBD)-specific  
169 immunoglobulin levels after both prime and boost vaccine doses. However, transplant recipients  
170 who had COVID-19 infection prior to vaccination displayed neutralizing antibodies to SARS-  
171 CoV-2 at baseline that increased following vaccination. Taken together, the disparate humoral  
172 immune response to SARS-CoV-2 vaccine as compared to natural infection in heart and lung  
173 transplant patients is suggestive of a failure of vaccines to induce immunologic priming in highly  
174 immunosuppressed patients, and points to the need for alternate immunization regimens for these  
175 populations.

176 The vast majority of participants received the two-dose BNT162b2 (Pfizer-BioNTech) mRNA  
177 vaccine (88%), with only two heart and lung transplant recipients (7.7%) receiving the two-dose  
178 mRNA-1273 (Moderna) vaccine and only one (3.8%) receiving the single-dose Ad26.COV2.S  
179 (Janssen) adenovirus-based vaccine; as a result, we were unable to assess vaccine-related  
180 outcomes and our outcomes in aggregate are largely reflective of responses to the Pfizer vaccine.  
181 Our data are consistent with recent studies showing response rates of 0–49% in heart and lung  
182 transplant recipients receiving the BNT162b2 mRNA vaccine (22, 24, 33, 34). These studies

183 provided evidence of lower anti-spike IgG levels in transplant recipients; we show that this is  
184 corroborated by lower neutralizing antibody titers as well. These studies also showed an  
185 association between poor response and the use of various immunosuppressive regimens,  
186 particularly those including DNA synthesis and calcineurin inhibitors. Compared with our  
187 findings, the higher response rates (up to 49%) observed in heart and lung transplant recipients in  
188 three of these studies (22, 24, 33) may reflect lower proportions of patients on combined  
189 calcineurin and DNA synthesis inhibition as well as maintenance steroids, whereas the vast  
190 majority of transplant recipients described in Havlin et al. (34) and in our cohort, who had a  
191 uniform lack of response to vaccine, are maintained on three-drug therapy.

192 The presence of robust neutralizing antibody titers in 3 of the 4 transplant recipients with prior  
193 COVID-19 infection in our study suggests that heavily immunosuppressed patients can  
194 nevertheless mount an effective humoral response to natural infection. This is in line with Havlin  
195 et al., who found that 85% of lung transplant recipients with SARS-CoV-2 infection developed  
196 spike-directed antibodies (34). The higher proportion of T<sub>PH</sub> cells in transplant patients who had  
197 prior COVID-19 infection may suggest an expansion in this population due to recent infection,  
198 which may in turn facilitate the boost in antibody responses seen in these individuals. A corollary  
199 to this is that the uniformly low numbers and proportion of T<sub>PH</sub> cells in uninfected transplant  
200 patients may underlie the inability of these individuals to mount spike-specific IgG responses.  
201 Our data indicate that mRNA vaccination may be sufficient to boost existing responses, as anti-  
202 spike antibody levels rose post-vaccination in patients with prior COVID-19 infection with  
203 similar kinetics to that of healthy controls; however, mRNA vaccination is a far weaker driver of  
204 immunologic priming of immune responses than natural infection.

205 The generation of long-lasting humoral immunity depends on a coordinated T and B cell  
206 response to antigen. Calcineurin inhibitors have been shown to impact antibody responses by  
207 inhibiting T follicular helper ( $T_{FH}$ ) cell differentiation, as well as naive B cell proliferation and  
208 plasmablast differentiation (4, 35). In our data, the substantial deficits in total and activated  
209  $CD4^+$  in transplant patients at baseline suggests that a failure to mount appropriate T cell help  
210 for B cell differentiation results in impaired class switching and memory B cell development. A  
211 limitation of our analysis is that pre-vaccine measurements were available only for 3 transplant  
212 patients and our “baseline” populations among transplant patients were mixtures of pre-vaccine  
213 and 9 days post the first vaccine dose timepoints; however, in the three subjects in whom both  
214 pre-vaccine and 9 days post the first vaccine dose timepoints were measured, the responses at the  
215 two timepoints were strongly correlated ( $r = 0.97$ ,  $>0.99$ , and  $>0.99$ , Fig. S7A), and no trends  
216 were observed that would suggest that the observed differences in  $CD4^+$  populations between  
217 transplant and control were artifactual (Fig. S7B).

218 It remains unclear why natural infection is able to overcome the reduction in baseline  $CD4^+$  T  
219 cells in many transplant patients (3 of 4 in our study); moreover, in our study, two uninfected  
220 transplant patients demonstrated an antibody response, albeit delayed (Fig. 3A and 3C). Delayed  
221 responses to SARS-CoV-2 vaccination have also been reported in kidney transplant and chronic  
222 dialysis patients (20, 36). The association between IgG responses and  $T_{PH}$  cells may offer a clue,  
223 as these cells have been implicated in extrafollicular B cell differentiation and maintenance (37)  
224 and COVID-19 infection induces expansion of  $T_{PH}$  cells (38) and increases in non-germinal  
225 center B cell responses (39).

226 Based on data in humans and monkeys, anti-spike protein IgG and anti-RBD IgG are strong  
227 immune correlates of protection to COVID-19 infection (40–42). The weakness of this response

228 in COVID-19-uninfected vaccinated heart and lung transplant recipients, demonstrated herein  
229 and in other studies, raises major concerns that despite vaccination, this population of patients is  
230 poorly protected from infection by standard vaccination strategies.

231

## 232 **Methods**

233 **Study participants and clinical and demographic data.** Eligible participants were heart and  
234 lung transplant recipients followed clinically at our institution and healthy volunteers of similar  
235 age and sex distribution. Healthy volunteers were solicited via a publicly accessible institutional  
236 website (<https://rally.partners.org/>) and local newsletters. Candidates for healthy controls were  
237 considered eligible if they were 30-80 years old (the same age range as enrolled transplant  
238 recipients), were not receiving immunosuppressive medications, and to enable rapid processing  
239 of obtained specimens, were living in eastern Massachusetts. All participants were enrolled prior  
240 to or up to two weeks after SARS-CoV-2 vaccination. Demographic and clinical data and  
241 vaccine type were collected from the electronic medical record and/or study participants.  
242 Evidence for prior COVID-19 infection was obtained from the electronic medical record.

243 **Demographics and clinical characterization of participants.** Eighteen heart and eight lung  
244 transplant recipients and 12 healthy volunteers receiving SARS-CoV-2 vaccination were  
245 enrolled. The age and sex distribution of the transplant and control groups were similar (Table  
246 1). About one half of the heart and lung transplant recipients were 1 to 5 years after  
247 transplantation, about 15% of each group were less than one year after transplantation, and one-  
248 third of heart and one-quarter of lung transplant recipients were 10 or more years after  
249 transplantation (Table 1). For the two-dose vaccines (BNT162b2 and mRNA-1273), the time  
250 between vaccine doses reflected each vaccine's prescribed dosing schedule, with the exception  
251 of one outlier, whose second dose was delayed due to intercurrent COVID-19 infection (Fig. S6).  
252 The vast majority of both heart and lung transplant recipient participants were maintained on a  
253 DNA synthesis inhibitor, a calcineurin inhibitor, and prednisone; about a quarter of both heart

254 and lung transplant recipients were also maintained on an mTOR inhibitor (Table 1). Lung  
255 transplant recipients were generally maintained on higher doses of prednisone than heart  
256 transplant recipients; whereas 75% (6/8) of lung transplant recipients were taking  $\geq 10$  mg of  
257 prednisone daily, only 6% (1/18) of heart transplant recipients were taking  $\geq 10$  mg daily. No  
258 other substantial medication differences between heart transplant and lung transplant participants  
259 were observed.

260 **Sample collection.** Serial blood samples were collected prior to vaccination (N=13),  
261 approximately 1 week after the first dose of vaccine (N=18, median 9 days, interquartile range  
262 [IQR, 25%-75%] 7-10 days), just prior to the second dose of vaccine (N=30, median 21 days,  
263 IQR 19-21 days after first dose), and at approximately 1 week (N=32, median 8 days, IQR 7-10  
264 days), 4 weeks (N=16, median 30 days, IQR 26-34 days), and 8-10 weeks (N=18, median 60  
265 days, IQR 60-69 days) after the second dose of vaccine. Baseline blood samples were defined as  
266 a sample collected prior to vaccination (N=12, including 4 transplant recipients and 8 healthy  
267 controls) or a blood sample collected approximately 1 week after the first dose of vaccine (N=9,  
268 all transplant recipients). Blood collection was either in the institutional Translational and  
269 Clinical Research Center or the participant's home by Partners HealthCare at Home. All samples  
270 were processed within 4 hours of phlebotomy. Blood samples were centrifuged, and plasma,  
271 serum, and PBMCs were isolated and cryopreserved at  $-180^{\circ}\text{C}$ . PBMC isolation was performed  
272 using BD cell preparation tubes with sodium heparin. Tubes were centrifuged at  $1800 \times g$  for 25  
273 minutes. PBMC were washed in HEPES-buffered Hanks saline solution, resuspended in FBS  
274 with 10% DMSO, and stored in liquid nitrogen.

275 **ELISA and neutralizing antibody assays.** Purified SARS-CoV-2 D614G spike protein receptor  
276 binding domain (RBD) and whole spike protein were generously provided by Aaron Schmidt.

277 RBD enzyme linked immunosorbent assays (ELISAs) to IgG in participant serum were  
278 performed as previously described (43). Measurements were performed in triplicate and the  
279 mean of the three replicates was used. Absolute concentrations were determined based on a  
280 standard curve fitted in R using the `drm` package. Inferred values above 1.25mg/uL, twice the  
281 value of the most concentrated standard, were replaced with 1.25 mg/uL, a procedure which  
282 affected only two samples (9d post dose 1 and 1d pre dose 2) from one individual, a heart  
283 transplant recipient with prior COVID-19. Neutralizing activity of plasma against SARS-CoV-2  
284 D614G, N501Y/D614G (representative of RBD of variant B.1.1.7), and E484K/N501Y/D614G  
285 (representative of RBD of variants B.1.351 and P.1) spike protein pseudoviruses were assayed as  
286 previously described (44). pCMV-SARS2SΔC D614G-gp41 was generated by PCR mutagenesis  
287 from pCMV-SARS2SΔC-gp41 and Gibson assembly. pCMV-SARS2SΔC N501Y/D614G-gp41  
288 and pCMV-SARS2SΔC E484K/N501Y/D614G-gp41 were obtained by Gibson assembly of the  
289 respective gBlocks (IDT) in pCMV-SARS2SΔC D614G-gp41.

290 **Flow cytometry.** To comprehensively quantitate proportions of B and T cell subsets at baseline,  
291 PBMCs were studied using multicolor flow cytometry. Preserved PBMCs were thawed and  
292 washed in complete DMEM. Prior to antibody staining, Fc receptors were blocked using Human  
293 TruStain FcX (BioLegend, 422302) at a concentration of 1:20 on ice for 15 minutes. Cells were  
294 stained sequentially, first for 20 minutes at 37°C, then washed and stained with a second cocktail  
295 of antibodies for 30 minutes at 4°C, as previously optimized for each clone. The following  
296 antibody panel was used to quantitate B and T cell subsets: anti-human HLA-DR-BUV395 (BD  
297 Biosciences, Clone Tu39, 1:400), anti-human CD45RA-BUV563 (BD Biosciences, Clone  
298 HI100, 1:600), anti-human CD38-BUV661 (BD Biosciences, Clone HIT2, 1:400), anti-human  
299 CCR7-BUV737 (BD Biosciences, Clone 3D12, 1:200), anti-human CD4-BUV805 (BD

300 Biosciences, Clone SK3, 1:100), anti-human CD20-BUV805 (BD Biosciences, Clone 2H7,  
301 1:100), anti-human CD25-BV421 (BioLegend, Clone BC96, 1:25), anti-human CD28-BV480  
302 (BD Biosciences, Clone CD28.2, 1:100), anti-human CD21-BV480 (BD Biosciences, Clone B-  
303 ly4, 1:100), anti-human CD11c-BV605 (BD Biosciences, Clone B-ly6, 1:100), anti-human CD10  
304 (BD Biosciences, Clone HI10 $\alpha$ , 1:25), anti-human PD1-BV711 (BD Biosciences, Clone EH12.1,  
305 1:100), anti-human CD86-BV750 (BD Biosciences, Clone FUN-1, 1:100), anti-human CD8-  
306 BV785 (BioLegend, Clone SK1, 1:400), anti-human IgD-BV785 (BioLegend, Clone 1A6-2,  
307 1:100), anti-human CXCR5-A488 (BD Biosciences, Clone RF8B2, 1:100), anti-human CD127-  
308 BB700 (BD Biosciences, Clone HIL-7R-M21, 1:50), anti-human CX3CR1-PE (BioLegend,  
309 Clone K0124E1, 1:25), anti-human CD27-PE-Dazzle (BioLegend, Clone M-T271, 1:100), anti-  
310 human CXCR3-PE-Cy7 (BioLegend, Clone G025H7, 1:50), anti-human CCR6-APC  
311 (BioLegend, Clone G034E3, 1:25), anti-human CD19-APC-R700 (BD Biosciences, Clone  
312 SJ25C1, 1:25), and anti-human CD3-APC-Vio770 (Milltenyi, Clone BW264/56, 1:200).

313 After staining, cells were washed with 1% BSA in PBS, centrifuged and resuspended in 1% BSA  
314 in PBS. Just prior to flow cytometry, dead cells were identified with SYTOX AADvanced Dead  
315 Cell Stain (Thermo Fisher Scientific, S10274, 1:1000). Flow cytometry was performed on a BD  
316 FACS Symphony cytometer (BD Biosciences, San Jose, CA), and rainbow tracking beads were  
317 used to ensure consistent signals between flow cytometry batches. FCS files were analyzed using  
318 FlowJo software (version 10.7.2). The surface markers used to define each cell type are provided  
319 in Table 2.

320 A single aliquot of PBMC was thawed and used for flow cytometry. Each aliquot corresponds to  
321 cells harvested from a single 8 mL CPT; however, absolute counts may reflect additional noise



322 incorporated during a single cycle of freezing and thawing. We therefore also report relative  
323 counts as a proportion of CD4+, CD8+ and CD19+ cells.

324 **Statistics.** Raw data were analyzed with R (45). Pairwise comparisons were performed using a  
325 Wilcoxon test. Correlation coefficients and associated p-values were calculated using Pearson's  
326 product-moment correlation coefficient. The proportion of subjects who responded to  
327 vaccination was calculated by Fisher's exact test. Response to vaccination for each subject was  
328 determined by a consistent rise in IgG ELISA over time. Data were displayed using ggplot (46).

329 **Study approval:** All study procedures involving human subjects were approved by the Mass  
330 General Brigham Human Research Committee, the governing institutional review board at  
331 Massachusetts General Hospital. Informed consent was received from participants prior to  
332 inclusion in the study, either in writing or by institutional review board-established verbal  
333 consent procedures employed during the COVID-19 pandemic. Participants were identified by  
334 numbers.

335 **Author contributions:**

336 J.E.L., designed research studies, recruited and consented patients, scheduled patients, conducted  
337 experiments, acquired data, analyzed data, wrote manuscript.

338 A.L., designed research studies, analyzed data, wrote manuscript.

339 M.G., conducted experiments, acquired data, edited manuscript.

340 C.A.P., designed research studies, conducted experiments, acquired data, edited manuscript.

341 Z.W., recruited and consented patients, scheduled patients, acquired data, edited manuscript.

342 K.B., recruited and consented patients, scheduled patients, edited manuscript.

343 P.A., recruited and consented patients, scheduled patients, edited manuscript.

344 H.L., conducted experiments, acquired data.

345 G.D.L., recruited patients, edited manuscript.

346 N.B., conducted experiments, acquired data.

347 T.L., recruited and consented patients, scheduled patients.

348 N.H., designed research studies.

349 S.S.P., designed research studies, analyzed data, edited manuscript.

350 M.B.G., designed research studies, recruited and consented patients, scheduled patients, analyzed  
351 data, wrote manuscript, raised funds to support studies.


352 **Acknowledgments**

353 This work was supported by the American Lung Association COVID-19 Action Initiative  
354 Research Award (to M.B.G.), the Cystic Fibrosis Foundation (to M.B.G.), Doris Duke Charitable  
355 Foundation Physician-Scientist Fellowship (to J.E.L.), a CRI/Bristol Myers Squibb Postdoctoral  
356 Fellowship (CRI 2993) (to M.G.), NIH U19 AI 110495 (to S.S.P.), and NIH UL1 TR 002541-01  
357 (to the Massachusetts General Hospital Translational and Clinical Research Center).

358 We are grateful to Grace Holland and Kathy Hall of the Massachusetts General Hospital  
359 Translational and Clinical Research Center, Gary Garberg and Jennifer Erickson of Partners  
360 HealthCare at Home, Meaghan Doucette, Aaron Schmidt, and Richelle Charles.


361 **Figures and legends**

362




363

364 **Figure 1: Levels of serum IgG to SARS-CoV-2 spike protein RBD among fully vaccinated**  
365 **COVID-19-naïve heart and lung transplant recipients.** Serum IgG binding to RBD, as  
366 measured by ELISA, at 8 days (A) or 30 days (B) after full vaccination, displayed by  
367 transplanted organ type. Data for the transplant recipients who had prior COVID-19 infection are  
368 excluded. Boxes, 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentile; whiskers, smallest and largest values in dataset  
369 up to 1.5x interquartile range. All data points are shown. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*\*,  $p <$   
370 0.0001.




371

372 **Figure 2: Plasma pseudovirus neutralization activity among fully vaccinated COVID-19-**  
373 **naive heart and lung transplant recipients.** SARS-CoV-2 neutralization, as measured by  
374 pseudovirus neutralization assay, at 8 days (A) or 30 days (B) after full vaccination, displayed by  
375 transplanted organ type. Data for the transplant recipients who had prior COVID-19 infection are  
376 excluded. Boxes, 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentiles; whiskers, smallest and largest values in dataset  
377 up to 1.5x interquartile range. All data points are shown. \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p <  
378 0.001; \*\*\*\*, p < 0.0001.



379

380 **Figure 3: Antibody trajectories over time in individual subjects.** (A-B) IgG binding to  
381 SARS-CoV-2 spike protein RBD over time, as measured by IgG ELISA, in COVID-19 naive  
382 subjects (A) or in subjects with prior COVID-19 infection (B) displayed by transplanted organ  
383 type. Neutralization activity over time in COVID-19 naive subjects (C) or in subjects with prior  
384 COVID-19 infection (D). All data points are shown.



385

386

387 **Figure 4: Immune cell subsets and cellular correlates of antibody response. (A)**  
 388 Quantification by flow cytometry of peripheral blood cells in COVID-19-naive individuals. **(B)**  
 389 Correlation between antibody response at day 8 after complete vaccination and baseline levels of  
 390 DR+ CD4 T peripheral helper (TPH) cells; DR+ CD4 T cells; DR+ CD4 T cells as a proportion  
 391 of total CD4+ cells at baseline, or TPH cells as a proportion of total CD4+ cells at baseline.  
 392 Least squares regressions (blue lines). Gray shading, 95% confidence interval (CI).  $R$ , correlation  
 393 coefficient. All data points are shown. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p <$   
 394  $0.0001$ .

395 Table 1. Demographic and clinical characteristics of cohort

Parameter	Range, description, or normal value	Transplant recipients			Healthy controls
		Heart (N=18)	Lung (N=8)	All (N=26)	
Age, median yrs. (range)		59 (41-76)	65 (35-76)	61 (35-76)	63 (37-74)
Female, n (%)		10 (56)	4 (50)	14 (54)	5 (42)
Race / ethnicity, n (%)	Hispanic	2 (11)	0 (0)	2 (8)	0 (0)
	Non-Hispanic	16 (89)	8 (100)	24 (92)	8 (67)
	Unknown	0 (0)	0 (0)	0 (0)	4 (33)
Years since transplant, n (%)	<1	3 (17)	1 (13)	4 (15)	n/a
	(1-5]	8 (44)	4 (50)	12 (46)	n/a
	(5-10]	1 (6)	1 (13)	2 (8)	n/a



	(10-15]	6 (33)	0 (0)	6 (23)	n/a
	≥15	0 (0)	2 (25)	2 (8)	n/a
Prior or concurrent COVID-19 infection, n (%)		2 (11)	2 (25)	4 (15)	0 (0)
Vaccine, n (%)	BNT162b2 (Pfizer-BioNTech)	15 (83)	8 (100)	23 (88)	9 (75)
	mRNA-1273 (Moderna)	2 (11)	0 (0)	2 (8)	3 (25)
	Ad26.COV2.S (Janssen)	1 (6)	0 (0)	1 (4)	0 (0)
Immunosuppressive medication regimen					
DNA synthesis inhibitor <sup>a</sup>		15 (83)	6 (75)	21 (81)	n/a
Calcineurin inhibitor <sup>b</sup>		18 (100)	7 (88)	25 (96)	n/a
mTOR inhibitor <sup>c</sup>		4 (22)	2 (25)	6 (23)	n/a
Prednisone, n (%)	none	2 (11)	0 (0)	2 (8)	n/a

	1-5 mg daily	14 (78)	1 (13)	15 (58)	n/a
	>5 to <10 mg daily	1 (6)	1 (13)	2 (8)	n/a
	≥10 mg daily	1 (6)	6 (75)	7 (27)	n/a

396 Abbreviations: n/a, not applicable. <sup>a</sup> Mycophenolate or azathioprine. <sup>b</sup> Tacrolimus or cyclosporine. <sup>c</sup> Evirolimus or  
397 sirolimus.

398 Table 2. Surface markers used to define T and B cell subsets

Subset	Defining surface markers
Naive CD4+	CD3+CD4+CD8-CCR7+CD45RA+
Effector-memory CD4+	CD3+CD4+CD8-CCR7-
Regulatory T cells	CD3+CD4+CD8-CCR7-CD127LoCD25Hi
Activated regulatory T cells	CD3+CD4+CD8-CCR7-CD127LoCD25Hi HLA-DR+
Follicular helper T cells	CD3+CD4+CD8-CCR7-CD127+/-CD25+/-CXCR5+
Peripheral helper T cells	CD3+CD4+CD8-CCR7-CD127+/-CD25+/-CXCR5-CX3CR1-CD28+HLA-DR+PD1+
Naïve CD8+	CD3+CD4-CD8+CCR7+CD45RA+
Effector-memory CD8+	CD3+CD4-CD8+CCR7-
CD8+ cytotoxic T cells	CD3+CD4-CD8+CCR7-CX3CR1+CD28-
Naïve B cells	CD3-CD19+IgD+CD27-
Unswitched memory B cells	CD3-CD19+IgD+CD27+

Switched memory B cells	CD3-CD19+IgD-CD27+
Double negative B cells	CD3-CD19+IgD-CD27-

399

400 **References**

- 401 1. Polack FP et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J.*  
402 *Med.* 2020;383(27):2603–2615.
- 403 2. Baden LR et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J.*  
404 *Med.* 2021;384(5):403–416.
- 405 3. Sadoff J et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.  
406 *N. Engl. J. Med.* 2021;384(23):2187–2201.
- 407 4. Wallin EF, Hill DL, Linterman MA, Wood KJ. The Calcineurin Inhibitor Tacrolimus  
408 Specifically Suppresses Human T Follicular Helper Cells. *Front. Immunol.* 2018;9:1184.
- 409 5. Araki K et al. mTOR regulates memory CD8 T-cell differentiation. *Nature*  
410 2009;460(7251):108–112.
- 411 6. Delgoffe GM et al. The mTOR kinase differentially regulates effector and regulatory T cell  
412 lineage commitment. *Immunity* 2009;30(6):832–844.
- 413 7. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. *Nat. Rev.*  
414 *Immunol.* 2012;12(5):325–338.
- 415 8. Ersching J et al. Germinal center selection and affinity maturation require dynamic regulation  
416 of mTORC1 kinase. *Immunity* 2017;46(6):1045–1058.e6.
- 417 9. Keating R et al. The kinase mTOR modulates the antibody response to provide cross-  
418 protective immunity to lethal infection with influenza virus. *Nat. Immunol.* 2013;14(12):1266–  
419 1276.

- 420 10. Raybuck AL et al. B cell-intrinsic mTORC1 promotes germinal center-defining transcription  
421 factor gene expression, somatic hypermutation, and memory B cell generation in humoral  
422 immunity. *J. Immunol.* 2018;200(8):2627–2639.
- 423 11. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after  
424 solid organ transplantation: a systematic review. *PLoS One* 2013;8(2):e56974.
- 425 12. Langedijk AC et al. Long-term pneumococcal vaccine immunogenicity following allogeneic  
426 hematopoietic stem cell transplantation. *Vaccine* 2019;37(3):510–515.
- 427 13. van Aalst M et al. The effect of immunosuppressive agents on immunogenicity of  
428 pneumococcal vaccination: A systematic review and meta-analysis. *Vaccine* 2018;36(39):5832–  
429 5845.
- 430 14. de Lavallade H et al. Repeated vaccination is required to optimize seroprotection against  
431 H1N1 in the immunocompromised host. *Haematologica* 2011;96(2):307–314.
- 432 15. Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to hepatitis A  
433 vaccination in immunocompromised travelers. *J. Infect. Dis.* 2015;212(3):378–385.
- 434 16. Werbel WA et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in  
435 solid organ transplant recipients: A case series. *Ann. Intern. Med.* [published online ahead of  
436 print: June 15, 2021]; doi:10.7326/L21-0282
- 437 17. Boyarsky BJ et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in  
438 Solid Organ Transplant Recipients. *JAMA* 2021;325(21):2204.
- 439 18. Benotmane I et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an

- 440 mRNA COVID-19 vaccine in kidney transplant recipients. *bioRxiv* 2021;  
441 doi:10.1101/2021.03.08.21252741
- 442 19. Grupper A et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in  
443 kidney transplant recipients without prior exposure to the virus. *Am. J. Transplant* [published  
444 online ahead of print: April 18, 2021]; doi:10.1111/ajt.16615
- 445 20. Rincon-Arevalo H et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in  
446 kidney transplant recipients and dialysis patients. *Sci Immunol* 2021;6(60).  
447 doi:10.1126/sciimmunol.abj1031
- 448 21. Sattler A et al. Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2  
449 (Tozinameran) prime-boost vaccination in kidney transplant recipients. *J. Clin. Invest.* [published  
450 online ahead of print: June 8, 2021]; doi:10.1172/JCI150175
- 451 22. Itzhaki Ben Zadok O et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart  
452 transplant recipients - a prospective cohort study. *Eur. J. Heart Fail.* [published online ahead of  
453 print: May 8, 2021]; doi:10.1002/ejhf.2199
- 454 23. Marinaki S et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ  
455 transplant recipients. *American Journal of Transplantation* 2021; doi:10.1111/ajt.16607
- 456 24. Peled Y et al. BNT162b2 vaccination in heart transplant recipients: Clinical experience and  
457 antibody response. *J. Heart Lung Transplant.* [published online ahead of print: April 21, 2021];  
458 doi:10.1016/j.healun.2021.04.003
- 459 25. Marion O et al. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines  
460 in Recipients of Solid Organ Transplants. *Ann. Intern. Med.* [published online ahead of print:

- 461 May 25, 2021]; doi:10.7326/M21-1341
- 462 26. Liu Y et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. *N.*  
463 *Engl. J. Med.* [published online ahead of print: May 12, 2021]; doi:10.1056/NEJMc2106083
- 464 27. Liu Y et al. Neutralizing Activity of BNT162b2-Elicited Serum. *N. Engl. J. Med.*  
465 2021;384(15):1466–1468.
- 466 28. Wu K et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. *N. Engl. J. Med.*  
467 2021;384(15):1468–1470.
- 468 29. Wu K et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from  
469 global SARS-CoV-2 variants. *bioRxiv* [published online ahead of print: January 25, 2021];  
470 doi:10.1101/2021.01.25.427948
- 471 30. Wang Z et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.  
472 *Nature* 2021;592(7855):616–622.
- 473 31. Wang P et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*  
474 2021;593(7857):130–135.
- 475 32. Rao DA et al. AI-19 T peripheral helper cells are expanded in the circulation of active SLE  
476 patients and correlate with CD21<sup>low</sup> B cells. *Adaptive Immunity* 2018; doi:10.1136/lupus-2018-  
477 lsm.19
- 478 33. Shostak Y et al. Early humoral response among lung transplant recipients vaccinated with  
479 BNT162b2 vaccine. *Lancet Respir Med* 2021;9(6):e52–e53.
- 480 34. Havlin J et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2



- 481 infection in lung transplant recipients. *J. Heart Lung Transplant*. [published online ahead of  
482 print: May 20, 2021]; doi:10.1016/j.healun.2021.05.004
- 483 35. De Bruyne R et al. Calcineurin inhibitors dampen humoral immunity by acting directly on  
484 naive B cells. *Clin. Exp. Immunol*. 2015;180(3):542–550.
- 485 36. Schrezenmeier EV et al. Immunogenicity of COVID-19 tozinameran vaccination in patients  
486 on chronic dialysis. *medRxiv* [published online ahead of print:  
487 2021];<https://www.medrxiv.org/content/10.1101/2021.03.31.21254683v1.abstract>. cited
- 488 37. Yoshitomi H, Ueno H. Shared and distinct roles of T peripheral helper and T follicular helper  
489 cells in human diseases. *Cell. Mol. Immunol*. 2021;18(3):523–527.
- 490 38. Meckiff BJ et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T  
491 Cells in COVID-19. *Cell* 2020;183(5):1340–1353.e16.
- 492 39. Kaneko N et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in  
493 COVID-19. *Cell* 2020;183(1):143–157.e13.
- 494 40. Corbett KS et al. Immune Correlates of Protection by mRNA-1273 Immunization against  
495 SARS-CoV-2 Infection in Nonhuman Primates. *bioRxiv* [published online ahead of print: April  
496 23, 2021]; doi:10.1101/2021.04.20.440647
- 497 41. Yu J et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*  
498 2020;369(6505):806–811.
- 499 42. Mercado NB et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus  
500 macaques. *Nature* 2020;586(7830):583–588.

- 501 43. Iyer AS et al. Persistence and decay of human antibody responses to the receptor binding  
502 domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol* 2020;5(52).  
503 doi:10.1126/sciimmunol.abe0367
- 504 44. Filbin MR et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-  
505 associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med*  
506 2021;2(5):100287.
- 507 45. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. *J. Comput. Graph.*  
508 *Stat.* 1996;5(3):299–314.
- 509 46. Wickham H et al. Welcome to the Tidyverse. *Journal of Open Source Software*  
510 2019;4(43):1686.